Vir Biotechnology (VIR) Is Up 19.4% After Strong Dual-Therapy Data in Hepatitis Delta Trial

In January 2026, Vir Biotechnology reported new positive data from its ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta, where combination therapy with investigational agents tobevibart and ...
Morningstar

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive ...